Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group.

Philochem is based in Zurich and was founded in 2006, with the mission to innovate ligand discovery and medicinal target identification.

Philochem scientists have pioneered innovative methodologies for the isolation of human monoclonal antibodies, for the discovery and validation of vascular markers of pathology and for the construction and screening of DNA-encoded chemical libraries of unprecedented quality and size. These technologies are integrated into drug discovery programs, with the aim to develop superior products for the imaging and treatment of serious angiogenesis-related diseases.

Philochem, in collaboration with ETH Zurich, developed a unique technique for the discovery of vascular targets that are preferentially and abundantly expressed in diseased tissues.